Nature Reviews Drug Discovery
Издатель: Springer Nature · ISSN 1474-1776,1474-1784 · 8 статей
-
Immunogenicity risk assessment of novel modalities using new approach methodologies
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/s41573-026-01562-9 Novel therapeutic modalities such as cell therapies and gene editors could potentially treat many diseases, but their clinical progression...
-
From hope to adoption: an industry perspective on the maturation of new approach methodologies
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/s41573-026-01583-4 From hope to adoption: an industry perspective on the maturation of new approach methodologies
-
Cancer vaccine development gets complicated
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...
-
How can gene therapy platforms be scaled up to treat thousands of rare diseases?
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
-
The expansion of kinase drug discovery: new targets, platforms and indications
Nature Reviews Drug Discovery, Published online: 11 November 2026; doi:10.1038/s41573-026-01551-y Over the past 25 years, kinase drug discovery has been one of the most active areas in pharmaceutical research and development. This...
-
First factor XIa inhibitor nabs FDA approval for stroke prevention
Nature Reviews Drug Discovery, Published online: 11 November 2026; doi:10.1038/d41573-026-00180-9 First factor XIa inhibitor nabs FDA approval for stroke prevention
-
Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress
Nature Reviews Drug Discovery, Published online: 09 November 2026; doi:10.1038/s41573-026-01552-x Conditional biologics (CBs) — protein therapeutics engineered to selectively activate within the tumour microenvironment — have the...
-
Histone lysine demethylases in the third decade: biology and therapeutic prospects
Nature Reviews Drug Discovery, Published online: 09 November 2026; doi:10.1038/s41573-026-01561-w Histone lysine demethylases regulate gene expression and chromatin structure and help to integrate epigenetics with metabolic and immune...